Degarelix

Generic Name: Degarelix

Brand Names: Firmagon, Degarelix Accord

Drug Type: Small Molecule

Chemical Formula: C_₈₂H_₁₀₃ClN_₁₈O_₁₆

CAS Number: 214766-78-6

Unique Ingredient Identifier: SX0XJI3A11

Background: Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer. Chemically, it is a synthetic linear decapeptide amide with seven unnatural amino acids, five of which are D-amino acids. FDA approved on December 24, 2008.

Indication: Degaralix is used for the management of advanced prostate cancer.

Associated Conditions: Advanced Prostate Cancer

Clinical Trials

Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer

Phase 3

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Goserelin
Drug: Degarelix
Drug: Bicalutamide

First Posted Date: 2009-01-28

Last Posted Date: 2013-11-11

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 42

Registration Number: NCT00831233

Locations: 🇪🇸
Fundación Puigvert, Barcelona, Spain
🇪🇸
Fundacion Hospital Alcorcón, Alcorcon, Spain
🇪🇸
Hospital de Basurto, Bilbao (Bizkaia), Spain

and more 29 locations

Dose Finding Trial With a New Treatment (Degarelix) for Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: degarelix

First Posted Date: 2009-01-08

Last Posted Date: 2023-11-30

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 189

Registration Number: NCT00819156

Locations: 🇧🇪
UZ Gasthuisberg, Leuven, Belgium
🇩🇪
Urologische Universitätsklinikum, Mannheim, Germany
🇭🇺
Pez Aladar County Hospital, Györ, Hungary

and more 35 locations

Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Degarelix

First Posted Date: 2009-01-08

Last Posted Date: 2023-11-30

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 172

Registration Number: NCT00818623

Locations: 🇩🇰
KAS Herlev, Herlev, Denmark
🇸🇪
Sahlgrenska Universitetssjukehuset, Göteborg, Sweden
🇫🇮
TAYS, Tampere, Finland

and more 27 locations

The Efficacy and Safety of FE 200486 in Treatment of Patients Suffering From Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Degarelix

First Posted Date: 2009-01-08

Last Posted Date: 2023-11-09

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 129

Registration Number: NCT00819247

Locations: 🇬🇧
Kings College Hospital, London, United Kingdom
🇬🇧
Stirling Royal Infirmary, Stirling, United Kingdom
🇬🇧
Bristol Royal Infirmary, Bristol, United Kingdom

and more 13 locations

Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: Degarelix 240 mg / 80 mg

First Posted Date: 2008-12-03

Last Posted Date: 2014-09-03

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 220

Registration Number: NCT00801242

Locations: 🇫🇷
Clinique Beausoleil, Montpellier, France
🇫🇷
CHU Hôtel-Dieu, NANTES cedex 1, France
🇫🇷
Hôpital Tenon, PARIS cedex 20, France

and more 48 locations

Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: degarelix

First Posted Date: 2008-08-20

Last Posted Date: 2013-01-18

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 37

Registration Number: NCT00738673

Locations: 🇩🇪
Wissenschaftskontor Nord, Rostock, Germany
🇩🇪
Martini Klinik, Hamburg, Germany
🇩🇪
Urologische Klinik, Planegg, Germany

and more 1 locations

Open-Label, Randomised Parallel-Group Study

Phase 3

Withdrawn

Conditions: Prostate Cancer

Interventions: Drug: Degarelix

First Posted Date: 2008-08-06

Last Posted Date: 2011-03-18

Lead Sponsor: Ferring Pharmaceuticals

Registration Number: NCT00728533

Phase II Study of ASP3550 in Patients With Prostate Cancer

Phase 2

Completed

Conditions: Prostatic Neoplasms

Interventions: Drug: ASP3550

First Posted Date: 2007-12-06

Last Posted Date: 2014-10-29

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 273

Registration Number: NCT00568516

Explorative Study of Degarelix for Treatment of Benign Prostatic Hyperplasia.

Phase 2

Completed

Conditions: BPH

Interventions: Drug: Degarelix

First Posted Date: 2007-09-11

Last Posted Date: 2015-05-04

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 52

Registration Number: NCT00527488

Locations: 🇩🇪
CRS Clinical Research Services Monchengladback GmbH, Monchengladbach, Germany

Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Degarelix

First Posted Date: 2007-05-02

Last Posted Date: 2011-03-23

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 133

Registration Number: NCT00468286

Locations: 🇺🇸
Regional Urology, Shreveport, Louisiana, United States
🇺🇸
The Urology Center, Greensboro, North Carolina, United States
🇺🇸
State College Urologic Association, State College, Pennsylvania, United States

and more 23 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy